Prevotella spp. “ Andre ” mikroorganismer Chlamydophila (Chlamydia) pneumoniae * Chlamydia trachomatis * Coxiella burnetii Legionella pneumophila Mycoplasma genitalium Mycoplasma hominis Mycoplasma pneumoniae * Arter, hvor erhvervet resistens kan være et problem Aerobe grampositive mikroorganismer Staphylococcus aureus (methicillin- resistent) + Aerobe gramnegative mikroorganismer Enterobacter cloacae * Escherichia coli * Klebsilla oxytoca Neisseria gonorrhoeae* + Organismer med nedarvet resistens Aerobe gramnegative mikroorganismer Pseudomonas aeruginosa * Aktivitet er tilfredstillende demonstreret i modtagelige bakteriestammer i kliniske studier ved de godkendte kliniske indikationer. # ESBL- producerende stammer er normalt resistente over for fluoroquinoloner. + Resistenshyppighed > 50% i et eller flere lande.
Prevotella spp. “ Other” micro-organisms Chlamydophila (Chlamydia) pneumoniae* Chlamydia trachomatis* Coxiella burnetii Legionella pneumophila Mycoplasma genitalium Mycoplasma hominis Mycoplasma pneumoniae* Species for which acquired resistance may be a problem Aerobic Gram-positive micro-organisms Staphylococcus aureus (methicillin-resistant)+ Aerobic Gram-negative micro-organisms Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Neisseria gonorrhoeae*+ Inherently resistant organisms Aerobic Gram-negative micro-organisms Pseudomonas aeruginosa *Activity has been satisfactorily demonstrated in susceptible strains in clinical studies in the approved clinical indications. # ESBL-producing strains are commonly resistant to fluoroquinolones + Resistance rate > 50% in one or more countries